Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Market Cap : $38.80 Mil (As of May. 28, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Reviva Pharmaceuticals Holdings's share price for the quarter that ended in Mar. 2024 was $3.78. Reviva Pharmaceuticals Holdings's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 27.92 Mil. Therefore, Reviva Pharmaceuticals Holdings's market cap for the quarter that ended in Mar. 2024 was $105.53 Mil.

Reviva Pharmaceuticals Holdings's quarterly market cap increased from Sep. 2023 ($110.53 Mil) to Dec. 2023 ($143.78 Mil) but then declined from Dec. 2023 ($143.78 Mil) to Mar. 2024 ($105.53 Mil).

Reviva Pharmaceuticals Holdings's annual market cap increased from Dec. 2021 ($41.71 Mil) to Dec. 2022 ($86.90 Mil) and increased from Dec. 2022 ($86.90 Mil) to Dec. 2023 ($143.78 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Reviva Pharmaceuticals Holdings's Enterprise Value for Today is $31.07 Mil.

Reviva Pharmaceuticals Holdings Market Cap Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Market Cap Chart

Reviva Pharmaceuticals Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

80.73

41.71

86.90

143.78

Reviva Pharmaceuticals Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Market Cap	Get a 7-Day Free Trial													85.69	132.73	110.53	143.78	105.53

Competitive Comparison of Reviva Pharmaceuticals Holdings's Market Cap

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Market Cap distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Market Cap falls into.

Reviva Pharmaceuticals Holdings Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Reviva Pharmaceuticals Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$5.15	*	27.9186
	=	$143.78

Reviva Pharmaceuticals Holdings's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )	=	Share Price (Q: Mar. 2024 )	*	Shares Outstanding (EOP) (Q: Mar. 2024 )
	=	$3.78	*	27.9186
	=	$105.53

Reviva Pharmaceuticals Holdings (NAS:RVPH) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Reviva Pharmaceuticals Holdings Market Cap Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014

Website

https://www.revivapharma.com

Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.

Executives

Purav Patel	director	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu	officer: Chief Financial Officer	19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp	10 percent owner	250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena	director, 10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc	director, 10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat	director, 10 percent owner, officer: President and CEO	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon	officer: Chief Medical Officer	19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin	director	19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019